TG Therapeutics Inc (TGTX)
16.48
-0.94
(-5.40%)
USD |
NASDAQ |
May 17, 16:00
16.48
0.00 (0.00%)
After-Hours: 20:00
TG Therapeutics Cash from Financing (Quarterly): 0.01M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.01M |
| December 31, 2023 | -0.001M |
| September 30, 2023 | 0.421M |
| June 30, 2023 | 47.05M |
| March 31, 2023 | 25.24M |
| December 31, 2022 | 0.049M |
| September 30, 2022 | 0.275M |
| June 30, 2022 | 0.135M |
| March 31, 2022 | -0.85M |
| December 31, 2021 | 56.00M |
| September 30, 2021 | -7.361M |
| June 30, 2021 | -7.162M |
| March 31, 2021 | -0.055M |
| December 31, 2020 | 403.39M |
| September 30, 2020 | 35.26M |
| June 30, 2020 | 241.09M |
| March 31, 2020 | 0.081M |
| December 31, 2019 | 98.35M |
| September 30, 2019 | 20.70M |
| June 30, 2019 | 28.28M |
| March 31, 2019 | 56.88M |
| December 31, 2018 | 4.694M |
| September 30, 2018 | 4.492M |
| June 30, 2018 | 52.02M |
| March 31, 2018 | 52.43M |
| Date | Value |
|---|---|
| December 31, 2017 | 14.74M |
| September 30, 2017 | 28.22M |
| June 30, 2017 | 3.796M |
| March 31, 2017 | 86.91M |
| December 31, 2016 | 1.421M |
| September 30, 2016 | 0.0446M |
| June 30, 2016 | 3.536M |
| March 31, 2016 | 0.0142M |
| December 31, 2015 | 0.0216M |
| September 30, 2015 | 15.74M |
| June 30, 2015 | 17.63M |
| March 31, 2015 | 35.33M |
| December 31, 2014 | 26.73M |
| September 30, 2014 | 24.20M |
| June 30, 2014 | 0.2728M |
| March 31, 2014 | 17.44M |
| December 31, 2013 | 0.0484M |
| September 30, 2013 | 37.92M |
| June 30, 2013 | 0.7868M |
| March 31, 2013 | 0.9369M |
| December 31, 2012 | -0.0845M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | -0.0555M |
| March 31, 2012 | 12.04M |
| December 31, 2011 | 9.795M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-7.361M
Minimum
Sep 2021
403.39M
Maximum
Dec 2020
47.05M
Average
0.348M
Median
Cash from Financing (Quarterly) Benchmarks
| Amicus Therapeutics Inc | -13.31M |
| Geron Corp | 147.80M |
| Editas Medicine Inc | 0.192M |
| G1 Therapeutics Inc | -8.722M |
| Mersana Therapeutics Inc | 5.829M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.207M |
| Cash from Investing (Quarterly) | -9.255M |
| Free Cash Flow | 20.28M |
| Free Cash Flow Per Share (Quarterly) | -0.0561 |
| Free Cash Flow to Equity (Quarterly) | -9.415M |
| Free Cash Flow to Firm (Quarterly) | -5.913M |
| Free Cash Flow Yield | 0.82% |